Laminar Pharma Email Formats
Biotechnology Research • 
Palma, Balearic Islands, Spain • 21-50 Employees
Laminar Pharma Email Formats
Laminar Pharma uses 4 email formats. The most common is {first name}.{last name} (e.g., john.doe@laminarpharma.com), used 70.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@laminarpharma.com | 76.5% |
{first initial}{last name} | jdoe@laminarpharma.com | 11.8% |
{first initial}.{last name} | j.doe@laminarpharma.com | 11.8% |
Key Contacts at Laminar Pharma
Nanette Cocero
Member Board Of Directors
Emilce Cano Urrego
Director Of Intellectual Property
Antonio José González Lara
Director Gerente En Laminar Pharmaceuticals Sa
Company overview
| Headquarters | Ctra Valldemossa Km. 7,4, ParcBit. Edif. 17 2º piso, Mód C-8, Palma de Mallorca, Illes Balears 07121, ES |
| Phone number | +34971439886 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Design, The Membrane Lipid Therapy (Mlt) |
| Founded | 2006 |
| Employees | 21-50 |
| Socials |
About Laminar Pharma
Laminar Pharma is a pioneering biopharmaceutical company that focuses on the discovery, rational design and development of a new generation of medicines that act through the innovative therapeutic strategy known as “Membrane-Lipid Therapy” (MLT). Laminar Pharma arose in 2006 as an academic spin-off to commercially develop new scientific know-how and applications generated by leading scientists at the University of the Balearic Islands (UIB) in Mallorca, Spain, headed by Prof. Pablo V. Escriba. Laminar Pharma aims to develop next-generation medicines, nutraceutical and cosmetic products based on the novel Membrane-Lipid Therapy (MLT) strategy, which targets membrane lipids and/or the structures they form, rather than directly targeting specific cellular proteins. MLT-based drugs specifically interact with and modulate the activity of key signal-transduction peripheral proteins involved in the pathogeny of serious diseases like cancer, CNS, inflammatory or metabolic diseases. Innovative MLT-based drugs will soon become reference treatments worldwide for serious diseases with important medical needs unmet, such as glioblastoma and other aggressive cancer malignancies, as well as neuro-degenerative, metabolic, cardiovascular or inflammatory diseases. These novel drugs will provide a safe and efficacious therapeutic alternative that will bring dramatic improvements in the clinical outcome and in the quality of life for an important number of patients with these pathologies.
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Laminar Pharma has 15 employees across 7 departments.
Departments
Number of employees
Laminar Pharma Tech Stack
Discover the technologies and tools that power Laminar Pharma's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
JavaScript libraries
Maps
JavaScript libraries
JavaScript libraries
Programming languages
Blogs
Analytics
Video players
UI frameworks
United Kingdom
Italy
Estonia
Australia
GermanyFrequently asked questions
4.8
40,000 users
